Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see whether the combination of two drugs called
pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want
to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. This
study will compare the effects of the combination of two drugs called pembrolizumab and
vorinostat with the effects of pembrolizumab alone. The U.S. Food and Drug Administration
(FDA) has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and
lung cancer and vorinostat to treat some forms of blood and lymph node cancers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute